RHYTHM PHARMACEUTICALS, INC. (RYTM): what the price assumes

In the published model solve dated 2026-Q2, anchored at $110.57, RHYTHM PHARMACEUTICALS, INC. (RYTM) is priced for today's economics sustained for ~19.5 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/RYTM

Headline

FieldValue
TickerRYTM
CompanyRHYTHM PHARMACEUTICALS, INC.
Current price$110.57/sh
CompositionNet product revenue 103% / License revenue -3%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid35.1x
Steady-state operating margin assumed35.9%
Must persist for19.5y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 11.1% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.7 years.

Reconcile: at the x-ray's 9.3% required return this reads ~14.8 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history-1.02σ
sustained it ~10 years at this level14%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset—0—
Earnings—0—
Relative8.65x2expensive
Growth7.38x2expensive

Families that call it expensive: Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=4)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$12.788.65xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$1.8161.09xyesBook value floor: BV/sh $1.81, ROE negative (excluded from median)
Two-Stage Excess ReturnAsset$1.6367.83xyesBook value with convergence: BV/sh $1.81, ROE converges to ke (excluded from median)
Discounted Future Market CapGrowth$55.631.99xyesRev $0.2B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.6x / 12.0x / 14.4x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$8.6612.77xyesMargin ramp: -50% → 12% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$12.788.65xyesRevenue $0.22B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Rhythm Pharmaceuticals (consolidated)operatingenterprise0.2B reported-currency—withheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net cash$232.2m
Interest coverage-10.0x
Share count CAGR (dilution)7.8%
Burning cashyes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Bull Case

The structural advantage here is a near-monopoly on a defined genetic biology. Rhythm's setmelanotide, sold as IMCIVREE, was the first and for years the only approved therapy targeting the melanocortin-4 receptor pathway, and the 10-K describes the lead product as approved for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency "confirmed by genetic testing" (accession 0001628280-26-012399). That genetic-confirmation gate is the moat: it defines a patient population a competitor cannot serve without its own MC4R agonist and its own diagnostic pull-through, and it gives the franchise pricing power that the broad GLP-1 obesity market does not have. Gross margin near 90% is the financial signature of that position.

The moat just widened materially. The FDA approved an expanded IMCIVREE indication for acquired hypothalamic obesity on March 19, 2026, on the strength of an 18.4% placebo-adjusted BMI reduction in the Phase 3 TRANSCEND trial, and the launch drew more than 150 patient start forms in its first six weeks (Rhythm IR, GlobeNewswire). That is a second rare population layered onto the same molecule and the same commercial machine, and Europe is following: the CHMP issued a positive opinion with a European Commission decision expected in the second quarter and launches anticipated in 2027 (Rhythm IR). Each new indication reuses the existing infrastructure, so incremental revenue carries the high franchise margin rather than a fresh commercial build.

The top line is compounding into that widened opportunity. Full-year 2025 net product revenue was roughly $194 million, about 50% above the prior year, and first-quarter 2026 global IMCIVREE sales reached $60.1 million against $37.7 million a year earlier (Rhythm earnings releases). At about 33x trailing revenue the price is demanding a long runway, but the near-term growth rate the price assumes is inside what the company has recently delivered.

Bear Case

The fragility starts with the capital structure, because a company still burning cash does not get to choose its own timeline. Rhythm reported a trailing operating loss near $197 million, no demonstrated through-cycle operating margin to normalize against, and the solvency read is explicit that years-to-repay "cannot be computed honestly" when operating profit is negative (internal solvency note). It ended the first quarter with about $340.6 million in cash and short-term investments, and the 10-K is candid that funding has come from "the issuance of common and preferred equity, the sale of assets and a Revenue Interest Agreement" (accession 0001628280-26-012399). Against full-year 2026 non-GAAP operating expense guidance of $385 million to $415 million, that runway requires the revenue ramp to keep pace or the company returns to the market, and equity issued at a depressed price is exactly the dilution a stock priced at 33x sales cannot absorb cheaply.

The second fragility is concentration. The same 10-K flags that the company does "not have long term supply agreements in place with all of our contractors involved with the manufacturing" of the weekly formulation and the follow-on candidates RM-718 and bivamelagon, a supply risk that "could delay, prevent or limit our ability to generate revenue" (accession 0001628280-26-012399). A single manufacturing disruption, label setback, or reimbursement pushback hits the only product, with no second franchise to cushion it.

The pipeline already delivered the kind of shock the bear case warns about. The Phase 3 EMANATE program, testing setmelanotide across four genetically defined MC4R-pathway substudies, failed to hit its primary endpoint in any of the four (web research). That matters twice over: it removes near-term label-expansion optionality that some of the price's nineteen-year runway implicitly leans on, and it is a reminder that the same molecule the whole valuation rests on does not work everywhere the biology suggests it might. The price assumes a roughly 36% terminal operating margin sustained for close to two decades. Only about one in seven comparable fast-growers historically held that kind of pace for even ten years, and EMANATE is a concrete example of how the long tail of that assumption can be cut short.

Valuation

With no normal operating profit yet, the price is read against sales rather than earnings. At roughly 33x trailing revenue, an enterprise value near 33x sales, the inversion solves to a business that eventually earns about a 36% operating margin and grows revenue at its 25% self-funding ceiling for close to nineteen years, computed at a 10.9% cost of capital. The near-term growth rate sits inside what the company has recently shown, so the stretch is in the duration: the price needs the ramp to persist far longer than most fast-growers manage.

The X-ray splits sharply by family because the company is pre-profit. Asset methods anchor on a $1.81 book value per share and produce floors near $2, which is why they read as wildly cheap-to-price and carry no information for a story stock. Earnings-power, residual income, DCF and the dividend models are all gated off by negative EBIT, negative EPS and a non-positive normalized operating number.

The honest summary is the characterization itself: no standard frame reaches today's price, so the holder is underwriting a bet beyond what assets, earnings, peers, or even modeled forward growth support. The two numbers that decide whether that bet pays are the durability of the revenue ramp and the cash runway that funds it to profitability. Both are visible and both are the points the bear case presses.

Catalysts

The defining catalyst already landed: on March 19, 2026 the FDA approved IMCIVREE for acquired hypothalamic obesity, based on an 18.4% placebo-adjusted BMI reduction in the Phase 3 TRANSCEND trial, and the U.S. launch drew more than 150 patient start forms in its first six weeks (Rhythm IR, GlobeNewswire). That expansion is now the swing factor for 2026 revenue, on top of a base where first-quarter 2026 IMCIVREE sales reached $60.1 million versus $37.7 million a year earlier (Rhythm earnings release).

Europe is the next gate. The CHMP issued a positive opinion recommending the acquired-hypothalamic-obesity expansion, with a European Commission decision anticipated in the second quarter of 2026 and commercial launches expected in 2027 (Rhythm IR). On the pipeline, the Phase 3 EMANATE program missed its primary endpoint in all four MC4R-pathway substudies, removing one avenue of label expansion and shifting attention to the follow-on candidates RM-718 and bivamelagon (web research, accession 0001628280-26-012399).

The number to track alongside the catalysts is the cash line against spend: the company ended the first quarter with about $340.6 million in cash and short-term investments and guided to $385 million to $415 million in full-year 2026 non-GAAP operating expense (Rhythm earnings release). Watch the hypothalamic-obesity uptake curve, the European launch timing, and whether the revenue ramp closes the gap to operating expense without a fresh equity raise.

Sources: Rhythm Pharmaceuticals FDA approval release (ir.rhythmtx.com, globenewswire.com); Rhythm Q1 2026 and Q4 2025 earnings releases (sec.gov 8-K exhibits); CHMP positive opinion release (ir.rhythmtx.com).

Peer Cohorts (Per Segment, With Filing Citations)

Rhythm Pharmaceuticals (consolidated) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive RYTM report on boothcheck